Search Results

Genomics solutions provider Integrated DNA Technologies (IDT) and Bio-IT company Molecular Health have entered into a global multi-year agreement, starting in the U.S., to integrate their next generation sequencing (NGS) capabilities.

Global genomics solutions provider Integrated DNA Technologies announced the expansion of its synthetic biology operations with the opening of a new 25,000 square-foot-site in Coralville, IA.

Global genomics solutions provider Integrated DNA Technologies is expanding its gene synthesis offerings with a new custom vector onboarding tool.

Life sciences companies Integrated DNA Technologies (IDT) and Element Biosciences, Inc. have bolstered their partnership with products to enable more efficient and streamlined next generation sequencing (NGS) workflows for users of the AVITI System, an innovative sequencing and multi-omics platform based on Element’s novel avidity base chemistry.

DNA Nanobots, a biotechnology leader in DNA nanoparticles engineered for targeted therapeutics, announced that it completed exclusive commercial licensing of a gene editing technology from the University of California Berkeley.

Complete Genomics, Inc. announced its partnership with Integrated DNA Technologies, a global genomics solutions provider, to develop an ecosystem of advanced compatible products based on Complete Genomics’ innovative DNBSEQ™ sequencing platforms.

With a mission to accelerate the pace of genomics, Integrated DNA Technologies (IDT), a leading provider of differentiated next generation sequencing (NGS) solutions, announces the availability of xGen NGS products designed exclusively for the Ultima Genomics UG 100™ platform.

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced the pricing of a public offering with gross proceeds to the Company expected to be approximately $12.0 million, before deducting placement agent fees and other estimated expenses payable by the Company.

Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that the New York State Department of Health (“NYSDOH”) approved the Company’s TR8™ PGx (“TR8") pharmacogenomic (PGx) testing service.